| 慢性淋巴细胞白血病治疗进展:第57届美国血液学会年会报道 |
| |
| 引用本文： | 李悦,徐卫,李建勇. 慢性淋巴细胞白血病治疗进展:第57届美国血液学会年会报道[J]. 白血病．淋巴瘤, 2016, 25(1): 29-32. DOI: 10.3760/cma.j.issn.1009-9921.2016.01.009 |
| |
| 作者姓名： | 李悦 徐卫 李建勇 |
| |
| 作者单位： | 210029,南京医科大学第一附属医院 江苏省人民医院血液科;210029,南京医科大学第一附属医院 江苏省人民医院血液科;210029,南京医科大学第一附属医院 江苏省人民医院血液科 |
| |
| 摘 要： | 慢性淋巴细胞白血病(CLL)是一种高度异质性的慢性B淋巴细胞克隆增殖性疾病.近年来,随着化学免疫、bcl-2抑制剂、BCR信号通路抑制剂、PD-1抑制剂和嵌合抗原受体的T细胞(CAR-T)等新型药物及治疗方法不断涌现,CLL的治疗效果和缓解程度不断提高.文章就2015年第57届美国血液学会(ASH)年会CLL的治疗进展进行报道.
|
| 关 键 词： | 白血病 淋巴细胞 慢性 美国血液学会年会 |
Treatment progress of chronic lymphocytic leukemia: reports from the 57th American Society of Hematology annual meeting |
| |
| Li Yue,Xu Wei,Li Jianyong. Treatment progress of chronic lymphocytic leukemia: reports from the 57th American Society of Hematology annual meeting[J]. Journal of Leukemia & Lymphoma, 2016, 25(1): 29-32. DOI: 10.3760/cma.j.issn.1009-9921.2016.01.009 |
| |
| Authors: | Li Yue Xu Wei Li Jianyong |
| |
| Abstract: | Chronic lymphocytic leukemia (CLL) is a chronic B-cell lymphoproliferative clonal disease with a highly heterogeneous clinical course. In recent years, with the emerging of immunochemotherapy, bcl-2 inhibitor, B-cell receptor signal transduction kinase inhibitors and the chimeric antigen receptor-T cell (CAR-T), more and more improvements were made in CLL therapy and remission. This report addressed the progress of CLL therapy in the 57th American Society of Hematology annual meeting. |
| |
| Keywords: | Leukemia lymphocytic chronic American Society of Hematology annual meeting |
| 本文献已被 万方数据 等数据库收录！ |
